28 October 2021 : Clinical Research
Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis
Stephen Johnson1ABCDEF, Nakul Katyal2DEF, Naureen Narula3DEF, Raghav Govindarajan2ABCDEF*DOI: 10.12659/MSM.933296
Med Sci Monit 2021; 27:e933296
Table 2 Summary of patients’ clinical characteristics* (n=39).
| Characteristic | No. of patients (%) |
|---|---|
| Positive AChR antibody test result | 35 (89.7) |
| MGFA class | |
| 2A | 14 (35.9) |
| 2B | 13 (33.3) |
| 3A | 8 (20.5) |
| 3B | 3 (7.7) |
| 4A | 1 (2.6) |
| Pre-existing comorbidities | |
| Anemia | 2 (5.1) |
| Asthma | 8 (20.5) |
| Atopic dermatitis | 1 (2.6) |
| Benign prostatic hypertrophy | 1 (2.6) |
| COPD | 16 (41.0) |
| Coronary artery disease | 2 (5.1) |
| Coronary heart disease | 1 (2.6) |
| Depression | 4 (10.3) |
| Diabetes | 5 (12.8) |
| Gastroesophageal reflux disease | 8 (20.5) |
| Hyperlipidemia | 4 (10.3) |
| Hypertension | 22 (56.4) |
| Hypothyroidism | 6 (15.4) |
| Lung cancer | 1 (2.6) |
| Pre-diabetes | 1 (2.6) |
| Prostate cancer | 1 (2.6) |
| Stroke | 4 (10.3) |
| Vitamin D deficiency | 1 (2.6) |
| None | 2 (5.1) |
| Number of comorbidities | |
| None | 2 (5.1) |
| 1 | 12 (30.8) |
| 2 | 9 (23.1) |
| 3 | 9 (23.1) |
| ≥4 | 7 (17.9) |
| MG-ADL score | |
| 2 | 3 (7.7) |
| 3 | 0 |
| 4 | 0 |
| 5 | 1 (2.6) |
| 6 | 4 (10.3) |
| 7 | 11 (28.2) |
| 8 | 15 (38.5) |
| 9 | 3 (7.7) |
| 10 | 1 (2.6) |
| 11 | 1 (2.6) |
| * Based on the last recorded value in the patient’s medical charts. AChR – acetylcholine receptor; COPD – chronic obstructive pulmonary disease; MG-ADL – Myasthenia Gravis – Activities of Daily Living; MGFA – Myasthenia Gravis Foundation of America. | |